09/10/2024
3:16 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/27/2024
6:49 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:03 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
3:16 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
3:59 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:31 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024
3:19 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
|
08/07/2024
3:41 PM | Halozyme Therapeutics (Subject)
Posard Matthew L. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/24/2024
4:48 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/24/2024
3:05 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/23/2024
3:11 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/22/2024
3:13 PM | Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/28/2024
3:51 PM | Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/27/2024
3:29 PM | Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/26/2024
3:16 PM | Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/20/2024
3:17 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
3:22 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/14/2024
3:17 PM | Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2024
3:40 PM | Halozyme Therapeutics (Subject)
Posard Matthew L. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/22/2024
4:24 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/07/2024
3:05 PM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/29/2024
4:54 PM | Duncan Barbara Gayle (Reporting)
Halozyme Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/29/2024
4:56 PM | Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/29/2024
5:01 PM | Halozyme Therapeutics (Issuer)
Krishnan Mahesh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/29/2024
5:05 PM | Halozyme Therapeutics (Issuer)
MATSUI CONNIE (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/29/2024
5:08 PM | Halozyme Therapeutics (Issuer)
Miyashita Akiko Moni (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/29/2024
5:11 PM | Halozyme Therapeutics (Issuer)
Posard Matthew L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/29/2024
4:51 PM | Connaughton Bernadette (Reporting)
Halozyme Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/26/2024
3:22 PM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/17/2024
6:22 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/26/2024
6:38 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
3:46 PM | Halozyme Therapeutics (Filer)
| Form ARS | |
03/15/2024
3:18 PM | Halozyme Therapeutics (Filer)
| Form DEFA14A | |
03/13/2024
4:22 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/13/2024
3:14 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
3:13 PM | Halozyme Therapeutics (Filer)
| Form PRE 14A | |
02/28/2024
5:49 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/28/2024
3:07 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/20/2024
5:53 PM | Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2024
5:55 PM | Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2024
5:59 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Invest before this deal closes on 9/18 (Ad) This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges as demand ramps up. The market for this type of fuel is projected to grow 1,500% by 2030.
Invest before this investment round closes on 9/18. Learn more about how you can become a shareholder before their planned Nasdaq listing |
02/20/2024
5:49 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
4:39 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
4:41 PM | Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
4:47 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/12/2024
5:19 AM | Artisan Partners Limited Partnership (Filed by)
Halozyme Therapeutics (Subject)
| Form SC 13G/A | |
02/01/2024
2:51 PM | Halozyme Therapeutics (Subject)
Invesco Ltd. (Filed by)
| Form SC 13G/A | |
01/17/2024
3:56 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2024
7:10 AM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/16/2024
3:26 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/13/2023
6:48 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2023
3:40 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2023
3:21 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/14/2023
3:19 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/06/2023
3:04 PM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2023
3:07 PM | Halozyme Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/17/2023
6:28 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2023
3:30 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
